You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

CLINICAL TRIALS PROFILE FOR PEGADEMASE BOVINE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for pegademase bovine

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01852071 ↗	Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1/Phase 2	2013-08-02	The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
NCT01852071 ↗	Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene	Completed	National Human Genome Research Institute (NHGRI)	Phase 1/Phase 2	2013-08-02	The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
NCT01852071 ↗	Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1/Phase 2	2013-08-02	The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
NCT01852071 ↗	Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene	Completed	University of California, Los Angeles	Phase 1/Phase 2	2013-08-02	The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for pegademase bovine

Condition Name

Chart
Table

Condition Name for pegademase bovine
Intervention	Trials
ADA-SCID	2
Severe Combined Immunodeficiency Due to ADA Deficiency	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for pegademase bovine
Intervention	Trials
Severe Combined Immunodeficiency	2
Immunologic Deficiency Syndromes	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for pegademase bovine

Trials by Country

Map
Table

Trials by Country for pegademase bovine
Location	Trials
United States	3
United Kingdom	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for pegademase bovine
Location	Trials
California	2
Maryland	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for pegademase bovine

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for pegademase bovine
Clinical Trial Phase	Trials
Phase 1/Phase 2	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for pegademase bovine
Clinical Trial Phase	Trials
Completed	2
Active, not recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pegademase bovine

Sponsor Name

Chart
Table

Sponsor Name for pegademase bovine
Sponsor	Trials
Orchard Therapeutics	3
University of California, Los Angeles	2
National Human Genome Research Institute (NHGRI)	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for pegademase bovine
Sponsor	Trials
Other	4
Industry	3
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.